UT researcher, with CureDuchenne support, launches company to treat DMD using CRISPR/Cas9 technology | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

UT researcher, with CureDuchenne support, launches company to treat DMD using CRISPR/Cas9 technology


Eric Olson, a molecular biologist, has spent more than half his life in the lab. Now, the 62-year-old University of Texas researcher and distinguished professor is a businessman as well.

Olson, director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine in Dallas, has teamed up with the nonprofit group CureDuchenne — through its investment arm — to form Exonics Therapeutics.

The new company, based in Cambridge, Massachusetts, will use the CRISPR/Cas9 gene-editing technique known as SingleCut with the aim of correcting up to 80 percent of the 3,000 mutations that cause Duchenne muscular dystrophy (DMD).

https://www.duchennexchange.org/wp-content/uploads/2018/06/Olson1.jpg